The RAF Proto Oncogene Serine/Threonine Protein Kinase pipeline drugs market research report outlays comprehensive information on the RAF Proto Oncogene Serine/Threonine Protein Kinase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the RAF Proto Oncogene Serine/Threonine Protein Kinase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
The report also covers products from therapy areas such as Oncology, Genetic Disorders, and Central Nervous System which include the indications Solid Tumor, Colorectal Cancer, Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis), and Unspecified Central Nervous System Disorders. It also reviews key players involved in RAF Proto Oncogene Serine/Threonine Protein Kinase targeted therapeutics development with respective active and dormant or discontinued products.
The RAF Proto Oncogene Serine/Threonine Protein Kinase pipeline targets constitutes close to 19 molecules. Out of which, approximately 14 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 4, 5, 3, 1, and 1 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 3, and 2 molecule.
RAF Proto Oncogene Serine/Threonine Protein Kinase overview
RAF proto-oncogene serine/threonine-protein kinase or proto-oncogene c-RAF is an enzyme is encoded by the RAF1 gene. Once activated the cellular RAF1 protein can phosphorylate to activate the dual specificity protein kinases MEK1 and MEK2 which in turn phosphorylate to activate the serine/threonine specific protein kinases, ERK1 and ERK2. It plays an important role in the control of gene expression involved in the cell division cycle, apoptosis, cell differentiation and cell migration.
For a complete picture of RAF Proto Oncogene Serine/Threonine Protein Kinase’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.